Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | BRS3 | P32247 | 1/20 | 0.47 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913559 | 0.90 | MEN1 (0.57) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL17984887 | 0.89 | MEN1 (0.56) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL2913307 | 0.86 | TMEM97 (0.60) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL17985354 | 0.84 | MEN1 (0.52) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL12706737 | 0.80 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL29883119 | 0.79 | KMT2A (0.63) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1038680 | 0.79 | KMT2A (0.63) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL5776313 | 0.78 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL16217190 | 0.78 | MEN1 (0.59) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL16220609 | 0.78 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | MEN1 1661/4885KMT2A 3583/4885NPC1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.